Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
This December, Achaogen released much data on 2 plazomicin trials[1]: the pivotal EPIC study comparing plazomicin / levofloxacin with meropenem / levofloxacin in cUTI is the one we want to look at today because it is interpretable, while the other trial called CARE is not. CARE is one of those observational Continue reading All Smiles at the Press Conference: Plazo+Levo Delivers
There is no doubt that immunity to human cytomegalovirus (CMV) is both cell-and antibody-mediated. Studies in transplant patients showed that absence of T-cell protection with chemotherapy is a set-up for recurrent and severe CMV disease. It was also shown that patients with pre-existing CMV antibodies are less likely to develop CMV Continue reading The Monoclonal Pursuit of the Next CMV Therapeutic
Meropenem stands out as an antibiotic to be used first in ESBL and MDR infections, given its efficacy profile and safety record (see earlier blog). It also would seem to be appropriate to use relatively high doses or prolonged infusion times – or both – to improve T>MIC for the Continue reading To Kill A Mocking Bug – of the CRKP or CRAB Variety